Prognostic Value of a Three-DNA Methylation Biomarker in Patients with Soft Tissue Sarcoma

Table 1

Clinical characteristics of soft tissue sarcoma patients in the TCGA database.

Characteristics	Groups	Patients
		Total		Training cohort		Testing cohort
		(N = 257)		(N = 129)		(N = 128)
		No.	%	No.	%	No.	%
Sex	Male	117	45.53	59	45.74	58	45.31
	Female	140	54.47	70	54.26	70	54.69
Age at diagnosis	Median	61		60		62
	Range	20–89		20–89		24–87
	<61	128	49.80	66	51.16	62	48.44
	≥61	129	50.20	63	48.84	66	51.56
Vital status	Alive	158	61.48	77	59.69	81	63.28
	Dead	99	38.52	52	40.31	47	36.72
Tissue of origin	Uterus	31	12.06	16	12.40	15	11.72
	Connective soft tissue	114	44.36	51	39.54	63	49.22
	Retroperitoneum	99	38.52	54	41.86	45	35.16
	Other	13	5.06	8	6.20	5	3.90
Histological type	FMS	39	15.17	13	10.08	26	20.31
	LPS	59	22.96	30	23.26	29	22.65
	LMS	104	40.47	56	43.41	48	37.50
	SS	10	3.89	6	4.65	4	3.13
	GCS	3	1.17	2	1.55	1	0.78
	MPNST	9	3.50	5	3.87	4	3.13
	US	33	12.84	17	13.18	16	12.50
Adjuvant treatment type	Pharmaceutical	137	53.31	70	54.26	67	52.34
	Radiation	120	46.69	59	45.74	61	47.66

FMS: fibromyxosarcoma; LPS: liposarcoma; LMS: leiomyosarcoma; SS: synovial sarcoma; GCS: giant cell sarcoma; MPNST: malignant peripheral nerve sheath tumor; and US: undifferentiated sarcoma.